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ABSTRACT
Purpose Antidepressants like the serotonin reuptake inhibi-
tors (SRIs) are often used concomitantly with tamoxifen (e.g.
for treatment of depression). This may lead to an additional
prolongation of the QTc-interval, with an increased risk of
cardiac side effects. Therefore we investigated whether there
is a drug-drug interaction between tamoxifen and SRIs result-
ing in a prolonged QTc-interval.
Methods Electrocardiograms (ECGs) of 100 patients were
collected at steady state tamoxifen treatment, with or without
concomitant SRI co-medication. QTc-interval was manually
measured and calculated using the Fridericia formula. Primary
outcome was difference in QTc-interval between tamoxifen
monotherapy and tamoxifen concomitantly with an SRI.
Results The mean QTc-interval was 12.4 ms longer when
tamoxifen was given concomitantly with an SRI (95%
CI:1.8–23.1 ms; P = 0.023). Prolongation of the QTc-
interval was particularly pronounced for paroxetine
(17.2 ms; 95%CI:1.4–33.0 ms; P = 0.04), escitalopram
(12.5 ms; 95%CI:4.4–20.6 ms; P < 0.01) and citalopram
(20.7 ms; 95%CI:0.7–40.7 ms; P= 0.047), where other agents
like venlafaxine did not seem to prolong the QTc-interval.
None of the patients had a QTc-interval of >500 ms.
Conclusions Concomitant use of tamoxifen and SRIs
resulted in a significantly higher mean QTc-interval, which
was especially the case for paroxetine, escitalopram and cita-
lopram. When concomitant administration with an SRI is
warranted venlafaxine is preferred.
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ESC European Society of Cardiology
hERG Human ether-a-go-go related
Ikr Repolarizing potassium currents
IQR Interquartile range
LBBB Left bundle branch block
QTc Heart-rate corrected QT interval
RBBB Right bundle branch block
SCD Sudden cardiac death
SNRI Serotonin norepinephrine reuptake inhibitor
SRI Serotonin reuptake inhibitor
SSRI Selective serotonin reuptake inhibitor
TdP Torsade des pointes
INTRODUCTION
One of the most common causes of cessation of therapeutic
use of drugs which have already been marketed is prolonga-
tion of the QT-interval, which is defined as a QT interval >
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470 ms in females and > 450 ms in males according to
European Society of Cardiology (ESC) guidelines (1,2). QT-
interval or the heart-rate corrected QT (QTc) interval pro-
longation is associated with higher risk of polymorphic ven-
tricular tachycardia or Torsade des Pointes (TdP), which may
ultimately lead to sudden cardiac death (SCD) (1,3). The
QTc-interval represents the duration between the onset of
ventricular depolarization and the completion of repolariza-
tion of the myocardium. Several risk factors are associated
with an increased risk for QTc-interval prolongation (e.g
hypopotassemia, renal impairment, use of diuretics and other
QTc-prolonging drugs and unmodifiable risk factors such as
age > 65 years and female gender) (1,4–6). Furthermore, it has
become evident that several classes of anti-cancer drugs are
associated with QT prolongation and, therefore, this offers a
great challenge in the treatment of cancer patients (7–9).
The suggested mechanism of drug-induced QTc-interval
prolongation is inhibition or reduced expression of the
Human ether-a-go-go related (hERG) gene that encodes a
potassium channel that regulates repolarizing currents (Ikr) in
the cardiomyocytes or inhibition of late sodium currents
(1,10). Inhibition of these Ikr results in a delay in the ventricu-
lar repolarization causing prolongation of the QT-interval
(Fig. 1). Some drugs are known Ikr inhibitors, but failed to
demonstrate a clinical significant QTc-interval prolongation
at dosages used in routine clinical practice (e.g. fexofenadine),
although some of these drugs still give an increased risk of
experiencing TdP (1). Therefore, the risk of experiencing
TdP is not fully linear with the extent of QTc-interval prolon-
gation. Combining QTc-prolonging drugs (drug-drug
interaction) may also increase the risk of SCD (1,8). The com-
bination of two known QTc-prolonging drugs may result in a
cumulative or synergistic prolongation of the QTc-interval
and thus increased risk for TdP (11,12).
The risk of drug-induced QTc-interval prolongation is de-
termined according to Adverse Drug Event Causality Analysis
into QTc-prolonging drugs with a ‘known’, ‘possible’ or ‘con-
ditional’ risk for TdP (13,14). A drug is categorized as a drug
‘with a known risk of TdP’ if there is substantial positive evi-
dence of prolongation of the QTc-interval and an association
with TdP. The risk is scored as ‘possible’ if there is substantial
evidence which supports the conclusion that drugs can pro-
long the QTc interval, but there is insufficient evidence that
these drugs are associated with TdP. Finally, the risk is scored
as ‘conditional’ if there is substantial evidence of QT-interval
prolongation with an association with TdP development but
only under certain conditions (e.g. overdosing) or because the
drug has shown ability to create one or more conditions that
facilitate induction of TdP (e.g. by inhibiting metabolism of
QTc-proloning drugs). Drugs with a ‘known’ risk for QTc-
interval prolongation are escitalopram and citalopram.
Venlafaxine, imipramine, nortriptyline and tamoxifen are
classified as ‘possible’ and paroxetine, amitriptyline, sertraline,
fluoxetine and fluvoxamine are classified as conditional
according to Crediblemeds®.
One of the anti-cancer drugs, which is a known Ikr inhibi-
tor, is the selective ER modulator (SERM) tamoxifen
(8,15,16). Since decades, tamoxifen is used in the treatment
of breast cancer, where it provides suppression of ER-
dependent proliferation of breast cancer cells and therefore
reduces the risk of disease recurrence and mortality.
However, tamoxifen may also lead to Ikr inhibition in cardiac
tissue and ultimately to prolongation of the QTc-interval (15).
After absorption tamoxifen is converted into several pharma-
cologically active metabolites of which endoxifen is the most
potent. The cytochrome P450 enzymes CYP2D6 and
CYP3A4 play a dominant role in the biotransformation of
tamoxifen (17). It has been shown that the use of CYP2D6
or CYP3A4 inhibitors or inducers may lead to a significant
alteration in tamoxifen and endoxifen exposure (18–20). One
of the classes of drugs that is known for its ability to inhibit
CYP2D6 are the serotonin reuptake inhibitors (SRIs) like the
selective serotonin reuptake inhibitors (SSRI) and the seroto-
nin norepinephrine reuptake inhibitor (SNRI) venlafaxine
(21). These drugs are frequently used (by breast cancer
patients) for the treatment of depression, anxiety disorders or
(tamoxifen-related) hot flashes (22). The most potent
CYP2D6-inhibiting SRIs are paroxetine and fluoxetine (21).
When coadministration of an SRI is necessary with tamoxifen
therapy, patients are often treated with weak CYP2D6-
inhibiting SRIs like citalopram or escitalopram to minimize
the risk of changes in endoxifen plasma concentrations
(19,20). However, SRIs such as citalopram and escitalopram
are also known to cause prolongation of theQTc-interval (23).
Since both tamoxifen and SRIs may prolong the QTc-in-
terval, the combined use of these drugs may result in an en-
hanced risk of prolongation of the QTc-interval and therefore
ventricular arrhythmias, especially in breast cancer patients
since they have often more additional risk factors (e.g. female
gender, often older age). At present it is unknown if the effect
of combined treatment on the QTc-interval is additive or
synergistic. Hence, the objective of this study was to determine
whether there is a clinically relevant drug-drug interaction




This observational study was performed between February
2012 and October 2018. Electrocardiogams (ECGs) were col-
lected in the Erasmus University Medical Center in
Rotterdam, the Franciscus Vlietland & Gasthuis in
Schiedam and the Elisabeth-Tweesteden hospital in Tilburg,
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the Netherlands. This study has focused on the QTc-interval
during treatment with tamoxifen monotherapy compared to
treatment with tamoxifen and SRIs (i.e. SSRIs, SNRIs and
tricyclic antidepressants). The study was approved by the local
ethics committee of the Erasmus Medical Center in
Rotterdam (MEC12–109).
Study Population
We included a total of 100 adult patients with breast cancer
for whom treatment with tamoxifen was indicated. Fifty
patients also used an SSRI, venlafaxine or a tricyclic antide-
pressant, which also inhibits serotonin reuptake and may in-
crease the risk for QTc-interval prolongation (e.g. amitripty-
line). ECGs were taken at any time interval following drug
intake. Patients were on tamoxifen treatment for at least
4 weeks. Patients were included either retrospectively or pro-
spectively. Patients should not have received chemotherapy or
radiotherapy within 4 weeks prior to the ECG-recording. If
patients were included prospectively, written informed con-
sent was obtained. If the ECG of patients showed a left or
right bundle branch block (LBBB/RBBB), atrial fibrillation
or other ECG abnormalities due to cardiac pathology, ischae-
mia or bigeminy, they were excluded from further analysis
owing to interference of these factors with the QTc-interval.
ECGs showing a QRS complex of >120 ms, RR intervals
>1800 ms (defined as the time between two consecutive R
waves) or < 500 ms or ECGs with a QTc interval > 700 ms
or < 300 ms were also excluded, since the QTc-interval could
not be reliably measured. In addition, patients who used other
strong inhibitors/inducers of CYP2D6 and/or CYP3A4
(according to the Flockhart table) were excluded from the
analysis (21). Medication with a ‘known’ risk of TdP according
to the CredibleMeds list of QTc-prolonging drugs, except for
tamoxifen and SRIs, was prohibited and considered as exclu-
sion criterion (13).
Outcome Measures and Data Collection
The primary outcomemeasure of this study was the difference
in QTc-interval duration between tamoxifen monotherapy
and tamoxifen therapy with concomitant use of SRIs.
Secondary outcomes were the difference in the prevalence of
QTc-interval prolongation between the two groups and the
identification of risk factors for QTc-interval prolongation.
QTc-interval prolongation was defined as a QTc-time of
>470 ms in females and > 450 ms in males, based on the
ESC guidelines (2). Twelve-lead ECGs were recorded and
QT-intervals were measuredmanually by the same researcher
for all patients, preferably from lead II, from the onset of the
QRS complex to the end of the T-wave, according to the
tangent method, and were corrected for heart rate using the
Fridericia formula (QTcF) (24). The Fridericia formula is for-
mulated as the QT-interval divided by the RR-interval to the
power 0.33 (QTcB =QT/(RR0.33)) (25). For each patient da-
ta on characteristics such as age, sex, medical history, tumor
localization, previous anti-cancer treatment, laboratory anal-
ysis (i.e. liver function [AST, ALT, bilirubin], renal function
[creatinin, glomerular filtration rate(eGFR)], electrolytes [so-
dium, potassium, calcium, magnesium]) and medication was
obtained from electronic patient records (HIX, Chipsoft b.v.,
Amsterdam, the Netherlands). ECGs were obtained during
tamoxifen or tamoxifen concomitant with an SRI therapy,
when steady state therapy for both therapies was reached (de-
termined as at least four weeks of use for tamoxifen and one
week for SRIs). A baseline ECG was determined as an ECG
before start of tamoxifen or SRI therapy.
Statistical Analysis
QTc-intervals were compared between patients receiving ta-
moxifen monotherapy and patients receiving tamoxifen with
concomitant SRI therapy. To detect a difference of 15 ms,
assuming a standard deviation for QTc-interval time of
26 ms, in mean QTc-interval between both groups with 80%
power, a total of one hundred patients was required.
Therefore, a total of fifty evaluable patients using tamoxifen
monotherapy and fifty evaluable patients using tamoxifen con-
comitant with an SRI were included in the study. A p value
≤0.05 was considered statistically significant. Data was ana-
lyzed using IBM SPSS Statistics version 24 (IBM
Corporation, Armonk, NY). A t-test for independent samples
was used to compare the mean QTc-interval between the















Fig. 1 Mechanism of QTc-interval prolongation. Serotonin reuptake inhibitors (SRIs) inhibit the hERG channel and therefore the Ikr (repolarizing potassium (K
+)
current) in the cardiomyocyte. This results in a delay of the ventricular repolarization time and therefore in a prolongation of the QTc-interval. Prolongation of the
QTc-interval may result in cardiac arrhythmias such as TdP.
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groups in mean age was also determined using a t-test. For the
other patient characteristics the chi-square test was used.
Moreover for age, renal function, sodium, potassium, calcium
and magnesium a Pearson correlation coefficient was estimat-
ed to determine the correlation with the QTc-interval.
Correlation for other parameters as tumor localization and
previous therapy (e.g. anthracyclines, trastuzumab and radio-
therapy) was estimated using a Spearman correlation coeffi-
cient. For the secondary outcome theQTc-interval was dichot-
omized as either prolonged if >470 ms for females or not
prolonged if otherwise, according to the ESC guidelines (2).
Difference in proportion of QT-interval prolongation between
groups was determined using the Fisher’s exact test. Univariate
logistic regression analysis was performed to determine associ-
ated risk factors. If there were any significant risk factors they
were put into a multivariate analysis.
RESULTS
Participants
A total of 111 breast cancer patients were initially included in
this study. Eleven patients were excluded due to a variety of
ECG abnormalities at baseline resulting in a total of 100
evaluable patients. Fifty patients were treated with tamoxifen
in combination with an SRI (further referred to as index
group) and 50 patients were treated with tamoxifen without
an SRI (further referred to as control group). All patients were
female. The median age of patients in the control group (60;
interquartile range (IQR) = 50–66 years) was significantly
higher than the median age of patients in the index group
(50; IQR= 45–59 years; P= 0.01). There were no other sta-
tistically significant differences between the two groups and
none of the patients experienced cardiac arrhythmias. The
most frequently used SRIs in the index group were venlafax-
ine (30%) and paroxetine (20%). A more detailed overview of
the patient characteristics is presented in Table I.
Primary Outcome Measures
Mean QTc interval was 407.5 ± 22.1 ms in the control group
and 419.9 ± 24.1 ms in the index group. This resulted in a
significant difference in mean QTc interval of 12.4 ms
(95%CI 1.8–23.1 ms; P= 0.023) (Table II). Heart rate was
not significantly different between the control group and the
index group.
Secondary Outcome Measures
Analysis with the Fridericia formula resulted in 1 patient with
a prolonged QTc-interval, which was in the control group.
This resulted in a prevalence of 2% in the control group and
a prevalence of 0% in the index group, which was a non-
significant difference (P= 1.0). None of the patients had a
QTc-interval of >500 ms. SRI subgroup analysis showed a
significant difference in mean QTc-interval time for paroxe-
tine (17.2 ms; 95%CI 1.4–33.0 ms; P= 0.04), escitalopram
(12.5 ms; 95%CI 4.4–20.6 ms; P = <0.01) and citalopram
(20.7 ms; 95%CI 0.7–40.7 ms; P= 0.047) compared to the
control group in contrast to the other SRIs, which did not
show a significant difference in QTc-interval (Table II).
For the known risk factors for QTc-interval prolongation,
only SSRI use (Spearman r = 0.25; P= 0.01), age (Pearson
r = 0.24; P = 0.02), plasma potassium levels (Pearson r =
−0.28, P = 0.02), renal dysfunction (Pearson r =−0.24; P=
0.04) and the use of >1 concomitant drugs used (Spearman
r = 0.23, P = 0.02) showed significant correlation with QTc-
interval duration. There were no other factors which showed
a significant correlation with QTc-interval in general
(Table III). Furthermore possible risk factors as tumor locali-
zation (left vs. right) and (pre)treatment with anthracyclines,
radiotherapy or trastuzumab did not show statistically signif-
icant correlation with QTc-interval in general. Univariate
analysis did not reveal any significant risk factors and therefore
a multivariate analysis was not performed. The odds ratios for
the individual risk factors could not be measured reliably,
since the prevalence of QTc prolongation was low.
DISCUSSION
To our knowledge, this is the first study that investigated the
additional risk of developing QTc- prolongation in patients
using tamoxifen in combination with an SRI. This study
showed a significant difference in the mean QTc-interval be-
tween patients treated with tamoxifen monotherapy and
patients treated with tamoxifen therapy concomitantly with
an SRI, suggesting an additional QTc-prolonging effect if
tamoxifen is combined with an SRI. Furthermore, in this
study 1% of the patients had a prolonged QTc-interval
(>470 ms). This prevalence is in line with other clinical find-
ings and a recent investigation in cancer patients treated with
conventional or targeted anti-cancer therapy (26,27).
In this study, ECGs were retrospectively or prospectively
collected during tamoxifen steady-state monotherapy or ta-
moxifen therapy combined with an SRI. One of the main
limitations of this study was the absence of a baseline measure-
ment in most of the patients. Therefore, a ‘change from base-
line’ analysis could not be performed. There was a significant
difference in mean QTc-interval time between the tamoxifen
monotherapy and tamoxifen with SRI treated patients, which
is most likely related to the additive effect of the SRI. As
mentioned earlier tamoxifen is an assumed QTc-interval pro-
longing agent, especially in higher doses (8,16). Furthermore
there is substantial evidence regarding QTc-interval
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Table I Patient characteristics
Characteristic Index group (N =50) (%) Control group (N =50) (%) P value of the difference
Age (Median, IQR)* 50 (45–59) 60 (50–66) 0.01*
- < 65 years 41 (82) 37 (74)
-≥ 65 years 9 (18) 13 (26)
Sex NA
- Female 50 50
Race 0.28
- Caucasian 45 (90) 45 (90)
- Arabic 4 (8) 1 (2)
- African 1 (2) 1 (2)
- Latino – 3 (6)
Breast cancer localization# 0.54
- Left 25 (50) 22 (44)
- Right 23 (46) 28 (56)
Trastuzumab pretreatment 0.20
- Yes 8 (16) 3 (6)
- No 42 (84) 47 (94)
Anthracycline pretreatment 1.0
- Doxorubicin 21 (42) 17 (34)
- Epirubicin 19 (38) 22 (44)
- No 10 (20) 11 (22)
Radiotherapy 0.69
- Yes 26 (52) 29 (58)
- no 24 (48) 21 (42)
Number of drugs 2 (0–6) 2 (0–4) 0.93
Tamoxifen dose 0.20
20 mg 45 (90) 49 (98)
40 mg 5 (10) 1 (2)
Type of antidepressant NA
- Venlafaxine 15 (30)
- Paroxetine 10 (20)
- Escitalopram 5 (10)
- Citalopram 5 (10)
- Amitriptyline 5 (10)
- Sertraline 4 (8)
- Fluoxetine 3 (6)
Other 3 (6)
Renal dysfunction 1 3 0.30
Electrolyte disturbances
- Hyponatremia 2 0 0.50
- Hypopotassemia 0 0 –
- Hypocalcemia 3 2 1.0
- Hypomagnesemia 1 2 1.0
Hepatic dysfunction 1 1 1.0
Antidiabetic use 4 (8) 3 (6) 1.0
Loopdiuretic use 0 (0) 1 (2) 1.0
Abbrevations: IQR interquartile range, NA not applicable, Other type of antidepressant were fluvoxamine (n =1),
imipramine (n =1) and nortriptyline (n =1). Renal dysfunction was defined as estimated Glomerular Filtration Rate
(eGFR)< 60 m/min/1,73m2 , Hyponatremia was defined as a sodium value< 136 mmol/l, Hypopotassemia was defined
as a potassium value< 3.5 mmol/l, hypocalcemia was defined as a calcium value< 2.2 mmol/l, hypomagnesemia was
defined as a magnesium value< 0.7 mmol/l and hepatic dysfunction was defined as increased bilirubin (>16umol/l),
increased alanine aminotransferase (ALAT) (>40 U/l) or increased aspartate transaminase (ASAT) (>35 U/l). Missing values:
Hepatic function (N =33), Sodium (N =31), potassium (N =27), calcium (N =60), magnesium (N =66) and renal
function (N=28); *= P value< 0.05. # For breast cancer localization the equationwasmade for left or right. Therewas 1
patient with breast cancer on both sides at primary diagnosis and 1 patient for which data regarding tumor localization was
unknown due to lack of information from the referring center. These patients were both excluded from this analysis
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prolongation by SRIs, showing an average increase in QTc-
interval of 10-20 ms. QTc-interval prolonging effects seem
most prominent in nortriptyline and citalopram with increases
of more than 30 ms (28,29). Therefore an additive effect of
SRIs seems possible on top of the QTc-interval prolonging
effects of tamoxifen. However, to determine whether the use
of an SRI in combination with tamoxifen is a significant/
clinically relevant factor influencing the QTc-interval, more
research is needed in patients having both a baseline ECG
during tamoxifen use and at least a second ECG where ta-
moxifen is used in combination with an SRI.
Interestingly, a subgroup analysis of the different SRIs
showed a significant increase of the QTc-interval for citalo-
pram, escitalopram and paroxetine, which is in line with the
classification on theCredibleMeds list. In this list, citalopram and
also escitalopram has been clearly associated with QTc-
interval prolongation. On this list paroxetine is classified as a
drug which gives a ‘conditional’ risk of TdP. Several addition-
al factors like antidiabetic drug use, renal dysfunction and
multiple drug use may have contributed to QTc-interval pro-
longation in some of these patients. Furthermore, patients in
the control group were significantly older than in the index
group. The QTc-interval increases with age, and therefore in
elderly patients, the criteria for QTc-interval prolongation will
be met more frequently in the index group. We do acknowl-
edge that due to limited sample size in the subgroup our study
was underpowered to make definitive conclusions regarding
individual drugs.
AlthoughQTc-interval prolongation is carefully investigat-
ed during early drug development, its actual influence on
overall survival remains unclear. It is clear that QTc-interval
prolongation can lead to ventricular tachyarrhythmias (e.g.
TdP) and SCD (1,3). A recent systematic review from
Arunachalam et al. showed that ventricular tachyarrhythmias
were observed in 2.6% of patients using QTc-interval pro-
longing drugs, however TdP (0.33%) and SCD (0.03%) were
relatively rare (27). Since the absolute risk of cardiac events is
small, physicians always need to weigh the benefits of cessation
of a QTc-interval prolonging drug to the disadvantage of
discontinuation of a potentially useful drug. If a QTc-
interval prolonging drug can be replaced by a non QTc-
interval prolonging agent, this should always be considered.
The interaction investigated in this study may be explained
at a pharmacodynamic or pharmacokinetic level. Both ta-
moxifen and SRIs inhibit the Ikr and therefore, both may
prolong the QTc-interval. Inhibition of CYP2D6 by SRIs
results in lower endoxifen plasma levels (especially for strong
CYP2D6 inhibitors like paroxetine) and possible more Ikr in-
hibition, because of the higher tamoxifen plasma levels.
However preclinical evidence suggests similar Ikr-inhibition
by both tamoxifen and its metabolites, making this a less likely
explanation (20,30–32). SRIs like fluoxetine and paroxetine
are well known strong CYP2D6 inhibitors, which could alter
endoxifen concentrations and deprive patients from optimal
oncologic therapy. Escitalopram, citalopram and venlafaxine
are weak CYP2D6 inhibitors and therefore are considered
safe when administered concomitantly with tamoxifen (20).
However, since escitalopram and citalopram are also ‘known’
QTc-interval prolonging drugs, the combination with tamox-
ifen is not desirable and venlafaxine may be a better alterna-
tive since it seems to prolong the QTc-interval in only a minor
extent, as was shown in this study (Table II). However more
research is needed to verify this point.
In conclusion, this study is the first clinical study that inves-
tigated the additional risk of QTc-interval prolongation in
patients using an SRI concomitantly with tamoxifen. There
was a significantly longer mean QTc-interval in the patients
who used an SRI, which tended to be most prominent in
patients receiving citalopram, escitalopram or paroxetine.
The other SRIs, like venlafaxine and fluvoxamine, were not
clearly associated with QTc-interval prolonging effects. Based
on our data we recommend avoiding citalopram,
Table II QTc interval
Mean QTc (Fridericia)
time (ms)± SD
Patients with QTc prolongation Mean Difference (ms) (95%CI) P value Mean Heart rate
(beats/min) ± SD
Tamoxifen monotherapy 407.5 ± 22.1 1 (2%) 70 ± 13.6
Tamoxifen with SSRI 419.9 ± 24.1 0 (0%)# +12.4 (1.8 to 23.1) P = 0.023* 69 ± 10.9
- Venlafaxine 408.8 ± 21.5 +1.3 (−11.4 to 14.0) 0.84
- Paroxetine 424.7 ± 29.2 +17.2 (1.4 to 33.0) 0.04*
- Escitalopram 420.0 ± 6.0 +12.5 (4.4 to 20.6) < 0.01
- Citalopram 428.2 ± 16.6 +20.7 (0.7 to 40.7) 0.047*
- Amitriptyline 428.8 ± 32.5 +21.3 (−0.1 to 42.5) 0.05
- Sertraline 424.3 ± 24.1 +17.0 (−5.6 to 39.6) 0.15
- Fluoxetine 414.7 ± 25.6 +7.2 (−18.7 to 33.1) 0.59
Legend: This table shows the QTc times and difference in QTc-interval between treatment groups. * P value <0.05. For the analysis of the differences an
independent samples t-test was used. #Difference in number of patients with QTc prolongation was not significant (P =1.0)
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escitalopram and paroxetine in tamoxifen treated women,
and use the others SRIs that do not have this QTc-
prolonging effect (e.g. venlafaxine and fluvoxamine) to mini-
mize the possible risk of TdP and cardiac arrhythmias. As the
degree of QTc-interval prolongation was limited, and none of
the patients in this study reached a QTc-interval of >500 ms,
routinely checking ECGs in patients on combined tamoxifen+
SRI treatment does not seem necessary. For patients who have
multiple other risk factors for QTc-interval prolongation and
are using paroxetine, escitalopram and citalopram checking
the QTc-interval duration may increase patient safety.
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